Clinical Scorecard: Increased FASN-driven lipogenesis in aged macrophages plays a role in the advancement of liver fibrosis

At a Glance

Key Highlights

• Middle-aged mice exhibited more severe liver fibrosis compared to young mice.
• Senescent macrophages showed upregulation of pro-inflammatory cytokines and chemokines.
• FASN protein stability was affected by both ubiquitin-proteasome and autophagy pathways.
• Conditioned medium from senescent macrophages promoted hepatic stellate cell activation.
• Pharmacological inhibition of FASN reduced DNA damage response in senescent macrophages.

Guideline-Based Recommendations

Diagnosis

• Evaluate liver function and immune microenvironment through histopathology and serum biochemistry.

Management

• Consider targeting senescent macrophages and FASN in therapeutic strategies for liver fibrosis.

Monitoring & Follow-up

• Monitor hepatic collagen deposition and fibrosis progression in patients with chronic liver diseases.

Risks

• Increased risk of cirrhosis and hepatocellular carcinoma due to advanced liver fibrosis.

Patient & Prescribing Data

Individuals with chronic liver diseases, particularly those aged 12 months or older.

Pharmacological strategies targeting FASN may mitigate liver fibrosis progression.

Clinical Best Practices

• Assess the presence of senescent macrophages in fibrotic livers.
• Utilize transcriptome sequencing to identify regulatory pathways in liver fibrosis.
• Implement strategies to modulate the senescence-associated secretory phenotype (SASP).

Related Resources & Content

• Liver fibrosis and its global health impact
• Cellular senescence and its role in liver fibrosis